Published in Gene Therapy Weekly, November 11th, 1996
"We are very encouraged with the results we have seen so far," said Richard Daifuku, M.D., Ph.D., Targeted Genetics. "The most exciting data to date come from the trial at Stanford University, where administration of the AAV-CFTR gene product resulted in consistent gene transfer, and persistence of the gene in one patient out to 70 days.
"CF gene therapies using other vectors have shown much...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.